Chinese coronavirus vaccine produces immune response in phase two trial

The results from the Chinese trial provide data from a wider group of participants than the phase 1 trial, which was published in May

covid-19, vaccine, coronavirus
Premium

Phase 1 trial involved 108 healthy adults and it demonstrated promising results.

IANS Beijing
A phase 2 trial of a Covid-19 vaccine candidate conducted in China has found that the vaccine is safe and induces an immune response, according to a new study published in the journal The Lancet.
This comes barely 24 hours after on Monday The Lancet only published that a Covid-19 vaccine developed by scientists at the Oxford University produces strong immune responses in both parts of the immune system, showed results of Phase I/II trial.
The results from the Chinese trial provide data from a wider group of participants than the phase 1 trial, which was published in May. Phase 1 trial

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jul 21 2020 | 12:49 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com